Objective Hepatitis C is an infectious disease caused by the hepatitis C virus (HCV), which affects liver and is mainly transmitted by blood-to-blood contact. Infection is often asymptomatic, but when chronicized it causes liver inflammation (chronic hepatitis). This condition can progress to fibrosis, cirrhosis and cancer. Socio-economical quality of life is seriously affected by several aspects including domestic environment and workplace. Besides any ethical issue, the impact on the European and national health systems has a major relevance due to high costs of pharmacological treatments.At present, no vaccine against HCV is available. Standard therapy is currently based on double or triple combination (peginterferon, ribavirin and protease inhibitor), but it is ineffective to reduce symptoms in about 40% of cases, while clearance from viremia is not achievable.The market for HCV drugs is set to rapidly grow in the forthcoming years as new and more effective therapies will be available. Despite many scientific publications have envisaged during the most recent years the design and the study of new compounds targeting the glycans of the glycoproteins of the HCV envelope (gp120), no such kind of compounds have been described until now.Recent patent publications (WO2008/090151and WO2011/064303) have described innovative HCV inhibitors targeting such glycoproteins of HCV envelope. Some of those compounds have been already tested in typical in vitro assays eliciting a remarkable inhibitory activity on HCV. It remains to assess their effectiveness by implementing additional work packages. The current comprehensive proposal has been designed to develop the scientific and technological bases to assess most of the findings required to enter into clinical studies in humans with new HCV inhibiting compounds. Fields of science medical and health scienceshealth sciencesinfectious diseasesRNA viruseshepatitis Cmedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccinesnatural sciencesbiological sciencesbiochemistrybiomoleculescarbohydratesmedical and health sciencesclinical medicineoncologymedical and health sciencesclinical medicinehepatology Programme(s) FP7-SME - Specific Programme "Capacities": Research for the benefit of SMEs Topic(s) SME-2012-1 - Research for SMEs Call for proposal FP7-SME-2012 See other projects for this call Funding Scheme BSG-SME - Research for SMEs Coordinator UNIVERSITA DEGLI STUDI DEL PIEMONTE ORIENTALE AMEDEO AVOGADRO EU contribution € 72 500,00 Address DUOMO 6 13100 Vercelli Italy See on map Region Nord-Ovest Piemonte Vercelli Activity type Higher or Secondary Education Establishments Administrative Contact Francesco Cellerino (Dr.) Links Contact the organisation Opens in new window Website Opens in new window Total cost No data Participants (7) Sort alphabetically Sort by EU Contribution Expand all Collapse all THERAPICON Italy EU contribution € 443 000,00 Address VIA MALACHIA MARCHESI DE TADDEI 21 20146 MILANO See on map Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Administrative Contact Paolo Alberto Veronesi (Prof.) Links Contact the organisation Opens in new window Website Opens in new window Total cost No data CYATHUS EXQUIRERE PHARMAFORSCHUNGSGMBH Austria EU contribution € 485 000,00 Address RUDOLFSPLATZ 2 1 8 1010 WIEN See on map Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Administrative Contact Mario Pinza (Dr.) Links Contact the organisation Opens in new window Website Opens in new window Total cost No data 3S PHARMACOLOGICAL CONSULTATION & RES.SRL Romania EU contribution € 482 500,00 Address STRADA SABINELOR 52 SECTORUL 5 050853 BUCURESTI See on map Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Administrative Contact Loredana Georgiana Manolache (Dr.) Links Contact the organisation Opens in new window Total cost No data INSTITUTULUL NATIONAL DE CERCETARE-DEZVOLTARE CHIMICO-FARMACEUTICA Romania EU contribution € 13 000,00 Address CALEA VITAN 112 031299 BUCURESTI See on map Activity type Research Organisations Administrative Contact Iuksel Rasit (Dr.) Links Contact the organisation Opens in new window Total cost No data PHARMA SERV INTERNATIONAL SRL Romania EU contribution € 13 000,00 Address STRADA SABINELOR 52 SECTORUL 5 050853 BUCURESTI See on map Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Administrative Contact Luigi Silvestro (Dr.) Links Contact the organisation Opens in new window Total cost No data Aurigon Life Science GmbH Germany EU contribution € 13 000,00 Address Bahnhofstrasse 9 - 15 D-82327 Tutzing See on map Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Administrative Contact Gundel Hager (Dr.) Links Contact the organisation Opens in new window Website Opens in new window Total cost No data DUKE CHEM SA Spain EU contribution € 13 000,00 Address AVINGUDA MARE DE DEU DE 99 08799 OLERDOLA See on map Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Administrative Contact Joan Amor (Mr.) Links Contact the organisation Opens in new window Total cost No data